Sarah Davis MPhys
The University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Tel: (+44) (0)114 222 5209
Fax: (+44) (0)114 222 0749
I returned to ScHARR in January 2010 after spending three years working on NICE Clinical Guidelines. I started in November 2006 as Senior Health Economist at the National Collaborating Centre for Nursing and Supportive Care which developed Clinical Guidelines for NICE. When this centre was merged with three others to form the National Clinical Guideline Centre (NCGC) in April 2009, I joined the NCGC as Health Economics Lead.
Prior to this period, I was a cost-effectiveness modeller within the HEDS section at ScHARR where I worked on NICE Technology Appraisals, NICE Clinical Guidelines, Health Technology Assessments and consultancy projects for the pharmaceutical industry.
I am currently Deputy Director of the NICE Decision Support Unit (DSU). The DSU is commissioned by The National Institute for Health and Clinical Excellence (NICE) to provide a research and training resource to support the Institute's Technology Appraisal Programme.
My research interests are cost-effectiveness modelling, technology appraisal, and clinical guideline development.
My teaching interests include decision modelling in health care and supporting non-health economists to engage with health economic evidence when developing guidance for the NHS.
Guideline Development Group member for the following NICE Clinical Guidelines:
- Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care (Nov 2006 to Feb 2008)
- Management of inadvertent perioperative hypothermia in adults (Nov 2006 to Apr 2008)
- Delirium: diagnosis, prevention and management (Jul 2008 to Jul 2010)
- Management of transient loss of consciousness in adults (Jun 2008 to Aug 2010)
- Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs (08/118/01)
- Various projects for the DSU (see link)
- Franklin M, Davis S, Horspool M, Kua WS & Julious S (2017) Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study.. Pharmacoeconomics. View this article in WRRO
- Julious SA, Horspool MJ, Davis S, Bradburn M, Norman P, Shephard N, Cooper CL, Smithson WH, Boote J, Elphick H, Loban A, Franklin M, Kua WS, May R, Campbell J, Williams R, Rex S & Bortolami O (2017) PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term - a cluster randomised controlled trial and economic evaluation.. Health Technol Assess, 20(93), 1-154. View this article in WRRO
- Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P & Gittoes N (2016) A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 1-406. View this article in WRRO
- Campbell F, Holmes M, Everson-Hock E, Davis S, Buckley Woods H, Anokye N, Tappenden P & Kaltenthaler E (2015) A systematic review and economic evaluation of exercise referral schemes in primary care: a short report. Health Technology Assessment, 19(60), 1-110. View this article in WRRO
- Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M & Taylor RS (2014) VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. International Journal of Technology Assessment in Health Care, 30(03), 312-324. View this article in WRRO
- Akunne A, Davis S, Westby M & Young J (2014) The cost-effectiveness of multi-component interventions to prevent delirium in older people undergoing surgical repair of hip fracture.. Eur J Orthop Surg Traumatol, 24(2), 187-195.
- Davis S & Wailoo A (2013) A review of the psychometric performance of the EQ-5D in people with urinary incontinence.. Health Qual Life Outcomes, 11, 20. View this article in WRRO
- Petkar S, Bullock I, Davis S & Cooper P (2013) Transient loss of consciousness: Summary of NICE guidance. Heart.
- Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P & Moxham T (2013) Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.. Age Ageing, 42(1), 14-20.
- Davis S, Westby M, Petkar S & Pitcher D (2013) Tilt testing is more cost-effective than implantable loop recorder monitoring as a means of directing pacing therapy in people with recurrent episodes of suspected vasovagal syncope that affect their quality of life or present a high risk of injury.. Heart, 99(11), 805-810.
- Davis S, Westby M, Pitcher D & Petkar S (2012) Implantable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained.. Europace, 14(3), 402-409.
- Bansback N, Davis S & Brazier J (2007) Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.. Eye (Lond), 21(12), 1455-1463.
- Brennan A, Akehurst R, Davis S, Sakai H & Abbott V (2007) The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.. Value Health, 10(1), 32-41.
- Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S & Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.. Health Technol Assess, 9(22), 1-160. View this article in WRRO